NextCell Pharma publishes Annual Report 2024/2025

May 4, 2026

NextCell Pharma AB (publ) (“NextCell” or the “Company”) publishes its Annual Report for the extended financial year September 1, 2024 – December 31, 2025. The Annual Report is available in Swedish as an appendix to this press release or on the company's website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL".

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Eric Gustafsson, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com

Websites:
NextCell Pharma AB: www.nextcellpharma.com
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk
QVance AB: www.qvance.se

LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye Nordic Growth AB is the company´s Certified Adviser.

About NextCell Pharma AB
NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord tissue. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications. In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five years. A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell’s subsidiaries include Cellaviva, Scandinavia’s largest private stem cell bank, and QVance, the Nordic region’s first dedicated provider of quality services for developers of advanced therapies.

Download attachment Read full press release on Cision (external link)

2022-07-28

NextCell Pharma publishes Interim Report 3 2021/2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period September 1, 2021 – May 31, 2022 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market

Read more Read more

2022-06-08

Patients in the first part of pediatric diabetes trial with NextCell’s ProTrans treated

The cell therapy company NextCell Pharma AB ("NextCell") today announces that all six children in the first part of the study have now been treated with ProTrans. Patients will be monitored during the summer after which the safety of treatment will be evaluated by an independent Data Safety and Mo

Read more Read more

2022-05-31

The European Patent Office intends to grant a Patent for Selection Algorithm

NextCell Pharma AB ("NextCell" or the "Company") today announces that the European Patent Office (EPO) has issued an Intention to Grant notice relating to the patent entitled "Allogeneic Composition" (publication number EP3752598). The patent describes the method of manufacturing the drug candidat P

Read more Read more

2022-05-24

NextCell invited to speak at Advance Therapies Congress in London

NextCell Pharma AB (“NextCell”) present the ongoing clinical trial program with the lead cell therapy drug candidate, ProTrans, at the Advanced Therapies Congress in London on May 24th-25th. The presentation will be given by NextCell’s CEO, Dr. Mathias Svahn on Wednesday.

Read more Read more

2022-04-28

NextCell Pharma publishes Interim Report 2 2021/2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2021 – February 28, 2022 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth M

Read more Read more

2022-04-26

NextCell is attending a conference for worldleading celltherapies

NextCell Pharma AB ("NextCell" or the"Company") is attending the International Society for Cell and Gene Therapy 2022 in San Francisco, May 4-7. The company is represented by Mathias Svahn, CEO who is a member of the Business Development and Finance Committee will participate in workshops, round t

Read more Read more

2022-04-07

First age group treated in paediatric diabetes study with ProTrans

NextCell Pharma AB ("NextCell") today announces that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years.

Read more Read more

2022-04-01

Cellaviva delivers stem cells to treat serious blood disease

NextCell Pharma AB ("NextCell" or the ”Company”) announces that the stem cell bank Cellaviva has released umbilical cord blood stem cells to Rigshospitalet, Denmark's leading hospital.

Read more Read more